Drug-screening guided treatment before surgery for HER2 breast cancer
Part of Cancer clinical trials.
This trial tests a treatment plan that is chosen using drug-testing in a lab (to see which medicines may work best) before surgery. It is for people with early-stage HER2-positive breast cancer, aiming to improve outcomes by guiding the right treatment early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have invasive breast cancer (not just non-invasive disease).
- Your tumor is HER2-positive (HER2 is a growth signal on the cancer).
- Your cancer is stage T2 or has spread to nearby lymph nodes.
- Your day-to-day function is good (ECOG 0 to 1, meaning you are able to care for yourself).
- Your cancer is not stage IV.
- You do not have inflammatory breast cancer.
- You do not have severe long-term health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
This study tests a new type of targeted therapy called an antibody-drug conjugate for HER2-positive breast cancer. It is given before surgery to shrink the tumor and may improve chance of cure.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Hear when a new HER2-positive Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.